Navigation Links
OGX-011 Shows Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study
Date:12/3/2008

    First-line trial currently shows median overall survival of 27.5 months
     for OGX-011 in combination with docetaxel and prednisone and a 16.9
         months overall survival for docetaxel and prednisone alone.

       Achievement of survival benefit milestone results in release of
                   all remaining escrowed shares of OGXI.

BOTHELL, WA and VANCOUVER, Dec. 3 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced positive survival results from a randomized Phase 2 clinical trial of OGX-011 in combination with docetaxel and prednisone ("the OGX-011 arm") compared to docetaxel and prednisone alone ("the control arm") for first-line treatment of metastatic castrate resistant prostate cancer. The current 10.6 month median overall survival advantage observed in the OGX-011 arm represents an increase over the median survival observed in the control arm. Docetaxel was approved by the FDA based on a survival advantage of 2.4 months over mitoxantrone.

Based on the median overall survival advantage, the Board of Directors of OncoGenex Pharmaceuticals has approved the release of all of the remaining shares held in escrow pursuant to agreements related to Sonus Pharmaceuticals' merger with OncoGenex Technologies described in its Proxy Statement filed with the SEC on July 3, 2008. The escrow agreements provided for the release of 50% of the original number of shares held in escrow following the demonstration of at least a two-month improvement in survival in the OGX-011 arm as compared to the control arm. All milestone shares have now been released from escrow; as of December 3, 2008 there are 5,513,643 shares outstanding.

The trial was conducted and data were analyzed by the National Cancer Institute of Canada, Clinical Trials Group and was supported by a grant from the NCI-C
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
2. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
3. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
6. NicOx Naproxcinod Shows Highly Significant Reduction in Daytime Blood Pressure Versus Naproxen
7. Potentia Pharmaceuticals Drug Candidate for Age-Related Macular Degeneration Shows Positive Safety Profile in Phase I Clinical Trial
8. Interim Analysis of Top-Line Data From Phase II/III Study Shows Favorable Efficacy & Safety for Cortheras Relaxin in Acute Heart Failure
9. New Research Shows Many Patients with Persistent Cough and Sputum Actually had Airway Obstruction Consistent with COPD
10. Nycomeds Daxas(R) Shows Encouraging Preliminary Results in Phase III COPD Studies
11. Jellyfish Protein Shows Potential to Help With Memory
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)... in Syracuse University,s College of Arts and Sciences ... synthesis of stainless nanoparticles. , Mathew M. Maye, ... three-year, $360,000 grant from the National Science Foundation ... metal stainless alloy nanostructures, the results of which ... lithium-ion batteries. , Maye,s approach is ...
(Date:7/20/2014)... When nuclear fuel gets recycled, the process releases radioactive ... contaminates basements with the related gas radon. A new ... research appearing July 20 in Nature Materials ... in but not out. , The CC3 material ... elements from nuclear fuel or air in buildings and ...
(Date:7/18/2014)... Illinois at Urbana-Champaign have demonstrated that an array ... used like traditional photographic film to record light ... wavelength of light (for example, distances less than ... microscope acts as a "nanocamera" whereas the pBNAs ... film, the effect (writing and curing) is seen ...
(Date:7/18/2014)... 2014 Emerging Nuclear Power Countries - ... , Summary , The latest report from GlobalData, Emerging ... Development Analysis to 2030 covers the emerging nuclear market ... comprehensive information on key market players and their global ... various countries across the world has also been estimated. ...
Breaking Biology Technology:Syracuse University chemist to use NSF grant to study materials chemistry, nanoscience 2A noble gas cage 2A noble gas cage 3'Nanocamera' takes pictures at distances smaller than light's own wavelength 2Emerging Nuclear Power Countries - Market Forecast, Key Companies and Development Analysis, Size, Share, Growth, Trend to 2030 2Emerging Nuclear Power Countries - Market Forecast, Key Companies and Development Analysis, Size, Share, Growth, Trend to 2030 3
... 9, 2011 PDL BioPharma, Inc. (PDL, the Company) (NASDAQ: ... offer, subject to market and other conditions, $135 million aggregate ... under the Company,s shelf registration statement filed with the U.S. ... Company also expects to grant the underwriters a 13-day overallotment ...
... La., May 9, 2011 Following a rigorous ... LLC (AE) have been recommended 1st for state ... (ITRS) component of the Board of Regents Support ... their proposal to develop breakthrough technology for harvesting ...
... Fla., May 9, 2011 Dyadic International, Inc. ... focused on the discovery, development, manufacture and sale ... industrial enzyme and biopharmaceutical industries, today announced that ... and development center in The Netherlands, will be ...
Cached Biology Technology:PDL BioPharma, Inc. Announces Proposed $135 Million Public Offering of New Convertible Senior Notes Due 2015 2PDL BioPharma, Inc. Announces Proposed $135 Million Public Offering of New Convertible Senior Notes Due 2015 3PDL BioPharma, Inc. Announces Proposed $135 Million Public Offering of New Convertible Senior Notes Due 2015 4PDL BioPharma, Inc. Announces Proposed $135 Million Public Offering of New Convertible Senior Notes Due 2015 5LSU-AgCenter and Aquatic Energy Recommended for Clean Technology Grant 2LSU-AgCenter and Aquatic Energy Recommended for Clean Technology Grant 3
(Date:7/21/2014)... hotspots in areas across Riau province on Sunday, July ... following a decline in rainfall. The number of ... what had been reported one day prior, which had ... in six regencies and municipalities, most of which were ... haze it creates could potentially spread via winds to ...
(Date:7/21/2014)... does the word "dog" have meaning? If you say ... you? , Kansas State University philosopher Elliott Wagner aims ... research, which focuses on long-standing philosophical questions about semantic ... philosophers and a mathematician are collaborating to use game ... , "If I order a cappuccino at a coffee ...
(Date:7/21/2014)... Mass. New studies being launched by neurobiologist ... will investigate how estrogens produced in the brains ... songs during a critical window during development. This ... in human children. , In a separate study, ... the idea that estrogens produced in the brain,s ...
Breaking Biology News(10 mins):Philosopher uses game theory to understand how words, actions acquire meaning 2Studying estrogens made by the brain may offer new insights in learning and memory 2Studying estrogens made by the brain may offer new insights in learning and memory 3
... date of the Neanderthal genome, scientists suggest an early ... say the authors, but do not share much else ... this week's issue of Science, also finds no evidence ... study helps to explain the evolutionary relationship between Homo ...
... molecules comprised of chains of repeating structures, are used in ... pipes to reduce flow drag to gene therapy. ... scission, and a new study by the University of Michigan ... previously thought about why polymers break when subjected to strong ...
... The Wistar Institute in Philadelphia and The Vienna Biocenter ... normal repression of the p53 protein, perhaps the single ... humans. , The new molecular pathway described in ... in the progression of many types of cancer. A ...
Cached Biology News:Genetic study of Neanderthal DNA reveals early split between humans and Neanderthals 2Genetic study of Neanderthal DNA reveals early split between humans and Neanderthals 3Scientists find new way to manipulate DNA 2Novel regulatory mechanism identified for key tumor suppressor p53 2Novel regulatory mechanism identified for key tumor suppressor p53 3
... Stabilizer is an aqueous solution that contains ... chemicals in a PBS buffer (phosphate buffered ... product contains a combination of 0.02% methylisothiazolone ... StabilCoat Plus Stabilizer provides optimum performance for ...
... ABgene's Protein Purification Plates are designed ... SDS-PAGE gels. The 96-well plates feature two ... ends of each well. The wells remain ... with buffer, during which time the protein ...
... pLivSelect is a ... for recombinant identification. Recombinant ... colony survival, eliminating the ... screening. This quick and ...
... Western Blot Signal Enhancer does for enzyme-/substrate-based blotting ... it increases the signal up to 10-fold (or ... ,The Western Blot Signal Enhancer membrane treatment ... added to your current Western blotting protocol. ...
Biology Products: